|  |  |
| --- | --- |
| Pharmacy and Therapeutics Committee Virtual Meeting  January 25, 2023  12:00 PM - 5:00 PM  **Zoom Meeting Registration:**  To attend the meeting from a PC, Mac, iPad, iPhone, or Android device, please click on the link below:  https://ahcccs.zoom.us/s/84698091464?pwd=SjAwYlVWWkZrT0hJK0lEWGZ5Sis4UT09 | |
| **Time** | **Topic** |
| **12:00 PM** | **Welcome and Introductions:** Suzanne Berman, RPH, AHCCCS Pharmacy Director  **P&T October 19, 2022 - Minutes Review and Vote** |
| **12:15 PM** | **Drug Utilization Initiatives for the CMS Drug Utilization Review Report –**  **Amanda Kiriakopoulos, PharmD - OptumRx** |
| **12:45 PM** | **Nineteen Non-Supplemental Rebate Class Reviews:**     1. Androgenic Agents – Hind Douiki, PharmD, Magellan    1. Public Testimony: None 2. Antidepressants, Others - Hind Douiki, PharmD, Magellan    1. Public Testimony: None 3. Antidepressants, SSRIs - Hind Douiki, PharmD, Magellan    1. Public Testimony: None 4. Antivirals – Topical - Hind Douiki, PharmD, Magellan    1. Public Testimony: None 5. Bone Resorption Suppression Agents - Hind Douiki, PharmD, Magellan    1. Public Testimony: None 6. Bronchodilators, Beta Agonists - Hind Douiki, PharmD, Magellan    1. Public Testimony: None 7. Colony Stimulating Factors - Hind Douiki, PharmD, Magellan    1. Public Testimony: None 8. Enzyme Replacement, Gaucher Disease - Hind Douiki, PharmD, Magellan    1. Public Testimony: None 9. Erythropoiesis Stimulating Proteins - Hind Douiki, PharmD, Magellan    1. Public Testimony: None 10. Hypoglycemics, Alpha-Glucosidase Inhibitors - Hind Douiki, PharmD, Magellan     1. Public Testimony: None 11. Hypoglycemics, Metformins – Jonas Terry, PharmD, Magellan     1. Public Testimony: None 12. Hypoglycemics, SGLT2s - Jonas Terry, PharmD, Magellan     1. Public Testimony: None 13. Immune Globulins - Jonas Terry, PharmD, Magellan     1. Public Testimony: None 14. Oral Oncology, Oral, Hematologic - Brand/Generic - Jonas Terry, PharmD, Magellan     1. Public Testimony: 15. Ophthalmics, Anti-Inflammatory Products - Jonas Terry, PharmD, Magellan     1. Public Testimony: None 16. Otic Antibiotics - Jonas Terry, PharmD, Magellan     1. Public Testimony: None 17. Pulmonary Atrial Hypertension (PAH) Oral and Inhaled Agents - Jonas Terry, PharmD, Magellan     1. Public Testimony: None 18. Thrombopoiesis Stimulating Proteins - Jonas Terry, PharmD, Magellan     1. Public Testimony: None 19. Ulcerative Colitis Agents - Jonas Terry, PharmD, Magellan     1. Public Testimony: None |
| **2:10 PM** | **New Drug Reviews:** Hind Douiki, PharmD, Magellan   |  |  |  | | --- | --- | --- | | ***Brand Name*** | ***Generic Name*** | ***Drug Class*** | | **Sotyktu**  **Rolvedon SubQ**  **Sulenca Oral & SubQ** | **Deucravacitinib**  **Eflapegastim-xnst**  **Lenacapavir** | **Cytokine and CAM Antagonist**  **Colony Stimulating Factors**  **HIV-AIDS** | |
| **2:20 PM** | **P&T Requests**  **Preferred Drug Additions:** Suzi Berman   * **Pregabalin** * **Lithium**   **Step Therapy Removal:** Suzi Berman   * **Symbicor** * **Dulera** * **Advair** |
| **2:30 PM** | **Break & Executive Session –** Kristen Haloski**,** PharmD, AAHIVP, Magellan |
| **4:00 PM** | **Public Therapeutic Class Votes – Hind Douiki**, PharmD, Magellan |
| **4:25 PM** | **Biosimilar Update: None** |
| **4:30 PM** | **Meeting Adjournment**  Future Meeting Dates: May 23, 2023, October 25, 2023 |